Antibodies targeting b-cell maturation antigen and methods of use
AssigneesMemorial Sloan Kettering Cancer Center, Eureka Therapeutics, Inc.
InventorsRenier J. Brentjens, Eric L. Smith, Cheng Liu
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
Claims30
An anti-B Cell Maturation Antigen (BCMA) single chain variable fragment (scFv), comprising a heavy chain variable region and a light chain variable region, wherein:
- (a) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 167, 168, and 169, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 170, 171, and 172, respectively;
- (b) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 185, 186, and 187, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 188, 189, and 190, respectively;
- or
- (c) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 119, 120, and 121, respectively;
- and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 122, 123, and 124, respectively.
A nucleic acid molecule that encodes an anti-BCMA antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein:
- (a) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 167, 168, and 169, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 170, 171, and 172, respectively;
- (b) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 185, 186, and 187, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 188, 189, and 190, respectively;
- or
- (c) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 119, 120, and 121, respectively;
- and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 122, 123, and 124, respectively.
A pharmaceutical composition comprising an anti-BCMA antibody or an antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, and a pharmaceutically acceptable carrier, wherein:
- (a) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 167, 168, and 169, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 170, 171, and 172, respectively;
- (b) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 185, 186, and 187, respectively and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 188, 189, and 190, respectively;
- or
- (c) the heavy chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 119, 120, and 121, respectively;
- and the light chain variable region comprises a CDR1, a CDR2, and a CDR3 sequence set forth in SEQ ID NOs:
- 122, 123, and 124, respectively.
Dependencies are inferred from the claim text.